IMMIX BIOPHARMA INC
Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$7.68
-3.76%
Alpha Vantage · 10/30/2026
One-year price history
Adjusted daily closes · 252 observations · as of Oct 30, 2026
1 month
-24.9%
3 months
-8.8%
6 months
-17.4%
1 year
+109.3%
Year to date
+46.9%
52-week range
$3.03 – $14.47
Fundamental snapshot
Latest reported period: Jun 30, 2026
Market cap
$549.4M
P/E
-13.8
P/B
2.4
P/S
—
Revenue
$0
Net income
-$39.92M
Diluted EPS
-0.88
Gross margin
—
Net margin
—
Return on equity
-38.40%
Total debt
$1M
Cash
$225.49M
Free cash flow
-$39.09M
Latest eight reported quarters
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Jun 30, 2026 | $0 | -$11.56M | — | — | -$11.76M |
| Mar 31, 2026 | $0 | -$10.09M | — | — | -$9.86M |
| Dec 31, 2025 | $0 | -$10.69M | — | — | -$11.19M |
| Dec 31, 2025 | $0 | -$10.69M | — | — | -$11.19M |
| Sep 30, 2025 | $0 | -$7.59M | — | — | -$6.28M |
| Jun 30, 2025 | $0 | -$6.62M | — | — | -$5.44M |
| Mar 31, 2025 | $0 | -$4.54M | — | — | -$1.75M |
| Dec 31, 2024 | $0 | -$4.81M | — | — | -$1.98M |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Recent IMMX news
All market newsNo ticker-linked stories are in the current archive.